首页> 外文OA文献 >>Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study

【2h】

>Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study

机译：>浮标方案的围手术期治疗可重演HER2 +晚期胃癌：回顾性研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Gangling Tong; Shuluan Li; Lin Lin; Lirui He; Li Wang; Guoqing Lv; Ruinian Zheng; Shubin Wang;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study [J] . Gangling Tong, Shuluan Li, Lin Lin, Cancer Management and Research . 2020,第4期

机译：具有浮标方案的曲妥珠单抗用于围手术期治疗可重症HER2 +晚期胃癌：回顾性研究
2. EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group [J] . Anna Dorothea Wagner, Heike I. Grabsch, Murielle Mauer, BMC Cancer . 2019,第1期

机译：EORTC-1203-GITCG-“创新”试验：单纯化疗与化疗加曲妥珠单抗相比，与化疗加曲妥珠单抗加培妥珠单抗在围手术期治疗HER2阳性，胃和胃食管交界处腺癌对病理反应率的影响：随机阶段EORTC-胃肠道癌组，韩国癌症研究组和荷兰上消化道癌组的II组间试验
3. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial [J] . Jifang Gong, Tianshu Liu, Qingxia Fan, BMC Cancer . 2016,第1期

机译：曲妥珠单抗联合奥沙利铂/卡培他滨治疗HER2阳性晚期胃癌（CGOG1001）一线治疗的最佳方案：一项多中心II期试验
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. HER2Delta16: a tumor-specific oncogene that drives tumorigenesis and trastuzumab resistance in HER2+ breast cancer. [D] . Huynh, Felicia C. 2015

机译：HER2Delta16：一种肿瘤特异性癌基因，可驱动HER2 +乳腺癌的肿瘤发生和曲妥珠单抗。
6. Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study [O] . Gangling Tong, Shuluan Li, Lin Lin, 2020

机译：曲妥珠单抗联合FLOT方案围手术期治疗可切除的HER2 +晚期胃癌的回顾性研究
7. EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group [O] . Anna Dorothea Wagner, Heike I. Grabsch, Murielle Mauer, 2019

机译：EORTC-1203-GITCG - “创新”-Trial：单独的化疗与化疗加上曲妥珠单抗，与化疗加曲妥珠单抗Plus Pertuzumab在病理反应率上的围手术期治疗中：随机阶段II-族胃肠道癌组，韩国癌症研究组和荷兰上GI-癌组的IN-CONTGROUP试验

>Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study

著录项

引文网络

相似文献

相关主题

期刊订阅